European Journal of Heart Failure最新文献

{"title":"Who We Recruit, Who We Miss: EARLY-HF and the Equity Gap in Heart Failure Research.","authors":"Amina Rakisheva, Vijay Chopra, Sivadasanpillai Harikrishnan","doi":"10.1093/ejhf/xuag311","DOIUrl":"https://doi.org/10.1093/ejhf/xuag311","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From SAFE-EXIT to SAFE-ACTION: Prediction Is Not Prescription.","authors":"Joanna Osmanska, Guillaume Baudry","doi":"10.1093/ejhf/xuag316","DOIUrl":"https://doi.org/10.1093/ejhf/xuag316","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consistency of the effect of digoxin across clinical subgroups in heart failure with reduced ejection fraction: insights from the DIG trial.","authors":"Misato Chimura, Kieran F Docherty, Ross T Campbell, Roy S Gardner, Alasdair D Henderson, Matthew M Y Lee, Mark C Petrie, Pardeep S Jhund, John J V McMurray","doi":"10.1093/ejhf/xuag320","DOIUrl":"https://doi.org/10.1093/ejhf/xuag320","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Baseline Characteristics and Utilization of Medical Therapies in Acute Hospitalized and Chronic Heart Failure Patients Enrolled in GRASP-HF: Differences Between ICARe-HF and Non-ICARe-HF Centres\".","authors":"Ovidiu Chioncel, Gianluigi Savarese, Cecile Laroche, Offer Amir, Mariya Tokmakova, Mathilde Boutard, Antonio Cannata, Hamlet Hayrapetyan, Hans-Eckart Sarnighausen, Noha El Ouafi, Emilie Soriano, Brenda Moura, Lars Lund, Marianna Adamo, Wendy Guillouche, Maurizio Volterani, Bernard Iung, Wilfried Mullens, Marco Metra","doi":"10.1093/ejhf/xuag317","DOIUrl":"https://doi.org/10.1093/ejhf/xuag317","url":null,"abstract":"<p><strong>Background: </strong>The Global Registries and Surveys Programme-Heart Failure (GRASP-HF) is a prospective, multicentre, international observational study assessing implementation of the 2021/2023 ESC-HF-Guidelines. GRASP-HF is aligned with the Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF) programme, which links centre-characteristics with guideline-implementation performance.</p><p><strong>Aims: </strong>To compare baseline characteristics, guideline-directed-medical-therapy (GDMT) implementation, and in-hospital outcomes between GRASP-HF patients managed in centres participating or not participating in the ICARe-HF programme.</p><p><strong>Methods: </strong>GRASP-HF patients were stratified by ICARe-HF participation, clinical settings, acute (AHF) vs chronic HF (CHF) and ejection fraction (EF) subtypes. Hierarchical multivariable logistic regression models evaluated associations with quadruple therapy implementation and in-hospital mortality.</p><p><strong>Results: </strong>Among 10,936 patients (63.3% CHF, 36.7% AHF), patients from ICARe-HF participating centres (51.3%) were older, more comorbid but with less severe congestion. In both CHF and AHF, ICARe-HF centres demonstrated greater GDMT utilization, particularly angiotensin receptor-neprilysin inhibitors and sodium-glucose-cotransporter-2 inhibitors. In HFrEF, quadruple therapy was more frequently implemented (47% vs 40% in CHF; 27% vs 24% at AHF discharge) and remained associated with ICARe-HF participation after adjustment, Odd Ratio (OR) =1.73, 95% Confidence Interval (CI) :1.17-2.55. Target doses remained suboptimal, particularly after AHF. Although crude in-hospital mortality was lower in ICARe-HF centres (2.3% vs 5.5%), this association was attenuated after multivariable adjustment (OR=0.87, 95% CI:0.48-1.56).</p><p><strong>Conclusions: </strong>Participation in the ICARe-HF programme was associated with more comprehensive implementation of contemporary GDMT, particularly in HFrEF. The association with in-hospital mortality was attenuated after adjustment and should be considered exploratory.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline directed medical therapy and decongestion in patients with acute heart failure.","authors":"Juan B Ivey-Miranda, Zachary L Cox, Veena S Rao, Julieta Moreno-Villagomez, Daniela Ramos-Mastache, Christopher Maulion, Lavanya Bellumkonda, Jeffrey M Turner, Yu Yamamoto, Javed Butler, Jan Biegus, Piotr Ponikowski, Jozine Ter Maaten, Kevin Damman, Julio Nunez, Mark C Petrie, F Perry Wilson, Jeffrey M Testani","doi":"10.1093/ejhf/xuag323","DOIUrl":"https://doi.org/10.1093/ejhf/xuag323","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Polypill: The Unmet Need and Great Hope for Heart Failure Patients.","authors":"Jan Biegus, Michael Böhm, Javed Butler, Piotr Ponikowski","doi":"10.1093/ejhf/xuag324","DOIUrl":"https://doi.org/10.1093/ejhf/xuag324","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF.","authors":"Jan Biegus, Beth Davison, Gad Cotter, Christopher Edwards, Jelena Čelutkienė, Ovidiu Chioncel, Alain Cohen-Solal, Gerasimos Filippatos, Maria Novosadova, Karen Sliwa, Marianela Barros, Albertino Damasceno, Matteo Pagnesi, Hadiza Saidu, Koji Takagi, Alexandre Mebazaa, Adriaan A Voors, Marco Metra, Piotr Ponikowski","doi":"10.1093/ejhf/xuag309","DOIUrl":"https://doi.org/10.1093/ejhf/xuag309","url":null,"abstract":"<p><strong>Aims: </strong>Loop diuretics (LD) are the cornerstone of congestion management in heart failure (HF), but whether their requirement can be reduced by optimizing disease-modifying therapy is unknown.</p><p><strong>Methods: </strong>In this post-hoc analysis of STRONG-HF (n=1,075 with post-randomization LD data), we assessed whether up-titration of guideline-directed medical therapy (GDMT) lowers LD demand, and whether LD dose reflects HF severity, predicts outcome, or modifies the benefit of high-intensity care. Patients were grouped by furosemide-equivalent dose; change at day 90 was compared by achievement of 100% target GDMT doses.</p><p><strong>Results: </strong>Higher LD doses marked more severe HF. Achieving 100% of target doses of all GDMT classes (RASi, beta-blocker, MRA) translated into a substantially lower diuretic requirement: furosemide-equivalent dose at day 90 fell by -21.94 (SD 52.46) mg versus -1.55 (SD 49.886) mg in those not reaching targets (p<0.001); beta-blockers showed the largest effect of any single class -18.42 (SD 49.61) mg, (p<0.001). LD dose category was not independently associated with the primary endpoint (all-cause death or HF rehospitalization at 180 days) or its components; only LD dose doubling was associated with higher all-cause mortality (adjusted HR 1.47, 95% CI 1.04-2.09), without association with the primary endpoint or rehospitalization (both p>0.05). The benefit of high-intensity care was consistent across LD dose groups (no treatment-by-dose interaction).</p><p><strong>Conclusions: </strong>GDMT optimization acted as diuretic-sparing therapy: reaching target doses, particularly of all three classes, was associated with markedly lower LD requirement. LD dose mirrored HF severity but neither consistently predicted outcome nor modified the benefit of up-titration.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical trajectory and disease progression in patients with cardio-renal-metabolic syndrome: the CaReMap observational study.","authors":"Federico Turoldo, Giulia Barbati, Cinzia Radesich, Vittorio Di Maso, Riccardo Candido, Manuela Bosco, Arjuna Scagnetto, Simona Barzaghi, Serena Falato, Carla Scognamillo, Andrea di Lenarda","doi":"10.1093/ejhf/xuag308","DOIUrl":"https://doi.org/10.1093/ejhf/xuag308","url":null,"abstract":"<p><strong>Background: </strong>Cardio-renal-metabolic (CRM) syndrome describes the pathophysiological interconnection among diabetes mellitus (DM), atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF), and chronic kidney disease (CKD). Limited studies simultaneously examine progression trajectories across all three conditions at the population level. We aimed to quantify the coexistence of CRM components, with a specific focus on patients with HF, and analyse survival and disease progression in a real-world setting.</p><p><strong>Methods: </strong>CaReMap, an observational cohort study, analysed data from an Italian Regional Epidemiological Repository. The selection period spanned from 2017 to 2022. Incident patients had a first diagnosis of DM, HF, or CKD after January 1, 2017. Prevalent patients were classified based on their baseline morbidity status on January 1, 2017. Descriptive statistics, Kaplan-Meier survival estimates, and cumulative incidence curves for cause-specific events were reported. The CRM stage was further defined according to disease coexistence and severity.</p><p><strong>Results: </strong>CaReMap included 71,694 adults with established CRM-related conditions (31.8% incident; 68.2% prevalent). Among incident patients, HF was associated with the highest probability of developing an additional diagnosis (60.4% at 6 years), while CKD showed the highest probability of death before a new diagnosis (43.3% at 6 years). In prevalent patients, the DM&HF group showed the highest cumulative incidence of further diagnoses (47.1% at 6 years). Across both incident and prevalent cohorts, HF and CKD patients experienced the steepest decline in overall survival.</p><p><strong>Conclusion: </strong>In this population-based Italian cohort, DM, HF, and CKD define distinct diagnostic trajectories with substantial competing risk of death. These findings provide real-world estimates of transition patterns and absolute risks that may inform risk stratification and integrated care pathways.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Implementation of guideline-directed medical therapy in patients with heart failure and obesity: European Journal of Heart Failure expert consensus document.","authors":"","doi":"10.1093/ejhf/xuag264","DOIUrl":"https://doi.org/10.1093/ejhf/xuag264","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digitoxin – first choice cardiac glycoside for HFrEF","authors":"Johann Bauersachs,Michael Böhm,Gerhard Poelzl,Stefan D Anker,Udo Bavendiek","doi":"10.1093/ejhf/xuag306","DOIUrl":"https://doi.org/10.1093/ejhf/xuag306","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"150 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}